• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无论有无贫血的缺铁状态:慢性心力衰竭患者不良结局的一个预测因素。

Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients.

作者信息

Rangel Inês, Gonçalves Alexandra, de Sousa Carla, Leite Sérgio, Campelo Manuel, Martins Elisabete, Amorim Sandra, Moura Brenda, Silva Cardoso José, Maciel Maria Júlia

机构信息

Cardiology Department, Centro Hospitalar de S. João, Porto, Portugal.

出版信息

Cardiology. 2014;128(4):320-6. doi: 10.1159/000358377. Epub 2014 Jun 7.

DOI:10.1159/000358377
PMID:24924145
Abstract

OBJECTIVE

To assess the prognostic significance of iron deficiency (ID) in a chronic heart failure (CHF) outpatient population.

METHODS AND RESULTS

We prospectively evaluated 127 patients with stable CHF and left ventricular ejection fraction ≤45%. Clinical and analytical data as well as information regarding the occurrence of the composite endpoint of overall mortality and nonfatal cardiovascular events were assessed. Among the 127 patients enrolled [81% men, median age: 62 years (25th-75th percentile: 53-68)], 46 (36%) patients had ID. Women, patients with higher plasma brain natriuretic peptide levels (>400 pg/ml) and with right ventricular systolic dysfunction presented ID more frequently (p < 0.05 for all). At 225 ± 139 days of follow-up, the composite endpoint occurred in 15 (12%) patients. It was more frequent in ID (24 vs. 5%, p = 0.001) and anemic patients (25 vs. 8%, p = 0.014). In a Cox regression analysis, ID was associated with a higher likelihood of composite endpoint occurrence (HR 5.00, 95% CI 1.59-15.78, p = 0.006). In a multivariable analysis adjusted for clinical variables, including the presence of anemia, ID remained a significant predictor of the composite endpoint (HR 5.38, 95% CI 1.54-18.87, p = 0.009).

CONCLUSION

In a CHF outpatient population, ID carried a higher risk of unfavorable outcome, irrespectively of the presence of anemia.

摘要

目的

评估缺铁(ID)在慢性心力衰竭(CHF)门诊患者中的预后意义。

方法与结果

我们前瞻性评估了127例稳定型CHF且左心室射血分数≤45%的患者。评估了临床和分析数据以及关于总体死亡率和非致命性心血管事件复合终点发生情况的信息。在纳入的127例患者中[81%为男性,中位年龄:62岁(第25 - 75百分位数:53 - 68岁)],46例(36%)患者存在ID。女性、血浆脑钠肽水平较高(>400 pg/ml)以及右心室收缩功能障碍的患者ID更为常见(所有p < 0.05)。在225±139天的随访中,15例(12%)患者出现复合终点。在ID患者(24%对5%,p = 0.001)和贫血患者(25%对8%,p = 0.014)中更常见。在Cox回归分析中,ID与复合终点发生的可能性较高相关(风险比5.00,95%置信区间1.59 - 15.78,p = 0.006)。在针对包括贫血在内的临床变量进行调整的多变量分析中,ID仍然是复合终点的显著预测因素(风险比5.38,95%置信区间1.54 - 18.87,p = 0.009)。

结论

在CHF门诊患者中,无论是否存在贫血,ID都具有更高的不良结局风险。

相似文献

1
Iron deficiency status irrespective of anemia: a predictor of unfavorable outcome in chronic heart failure patients.无论有无贫血的缺铁状态:慢性心力衰竭患者不良结局的一个预测因素。
Cardiology. 2014;128(4):320-6. doi: 10.1159/000358377. Epub 2014 Jun 7.
2
Iron deficiency in chronic heart failure: an international pooled analysis.慢性心力衰竭中的缺铁:国际汇总分析。
Am Heart J. 2013 Apr;165(4):575-582.e3. doi: 10.1016/j.ahj.2013.01.017. Epub 2013 Feb 22.
3
Prognostic usefulness of anemia and N-terminal pro-brain natriuretic peptide in outpatients with systolic heart failure.贫血与N末端脑钠肽前体对收缩性心力衰竭门诊患者的预后价值
Am J Cardiol. 2007 Nov 15;100(10):1571-6. doi: 10.1016/j.amjcard.2007.06.064.
4
Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure.慢性心力衰竭门诊患者新发、短暂性和持续性贫血的评估及长期预后
J Am Coll Cardiol. 2008 Feb 5;51(5):569-76. doi: 10.1016/j.jacc.2007.07.094.
5
Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.静脉注射铁剂可降低合并慢性心力衰竭和肾功能不全的贫血患者的N末端脑钠肽前体水平。
J Am Coll Cardiol. 2007 Oct 23;50(17):1657-65. doi: 10.1016/j.jacc.2007.07.029.
6
Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis.铁缺乏症在有和没有心力衰竭的多民族亚洲人群中的流行情况、临床相关性、功能意义和预后。
Eur J Heart Fail. 2014 Oct;16(10):1125-32. doi: 10.1002/ejhf.161. Epub 2014 Sep 11.
7
Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study.铁缺乏与慢性心力衰竭患者健康相关的生活质量:一项多中心欧洲研究的结果。
Int J Cardiol. 2014 Jun 15;174(2):268-75. doi: 10.1016/j.ijcard.2014.03.169. Epub 2014 Apr 3.
8
Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure.缺铁预测收缩性慢性心力衰竭患者运动能力受损。
J Card Fail. 2011 Nov;17(11):899-906. doi: 10.1016/j.cardfail.2011.08.003.
9
A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes.静脉铁蔗糖联合促红细胞生成素治疗老年晚期慢性心力衰竭伴心肾贫血综合征的长期疗效的初步评价:对神经激素激活和临床结局的影响。
J Card Fail. 2009 Nov;15(9):727-35. doi: 10.1016/j.cardfail.2009.05.010. Epub 2009 Jun 27.
10
Iron deficiency: an ominous sign in patients with systolic chronic heart failure.缺铁:收缩性慢性心力衰竭患者的不祥之兆。
Eur Heart J. 2010 Aug;31(15):1872-80. doi: 10.1093/eurheartj/ehq158. Epub 2010 Jun 21.

引用本文的文献

1
Prevalence and Adverse Outcomes of Iron Deficiency in Heart Failure.心力衰竭中铁缺乏的患病率及不良后果
Curr Cardiol Rev. 2025;21(5):104-111. doi: 10.2174/011573403X351268250130070459.
2
Impact of Intravenous Iron in patients with heart failure and Iron Deficiency: an updated Meta-analysis of Randomized controlled trials.静脉注射铁剂对心力衰竭合并缺铁患者的影响:随机对照试验的最新荟萃分析
BMC Cardiovasc Disord. 2024 Dec 3;24(1):695. doi: 10.1186/s12872-024-04368-y.
3
Prevalence and independent predictors of Iron deficiency in Yemeni patients with congestive heart failure: a retrospective cross-sectional study.
也门充血性心力衰竭患者铁缺乏症的患病率及独立预测因子:一项回顾性横断面研究。
Sci Rep. 2024 Nov 21;14(1):28901. doi: 10.1038/s41598-024-78556-3.
4
Prognostic impact of iron deficiency in new-onset chronic heart failure: Danish Heart Failure Registry insights.缺铁对新发慢性心力衰竭的预后影响:丹麦心力衰竭登记研究的见解
ESC Heart Fail. 2025 Apr;12(2):1346-1357. doi: 10.1002/ehf2.15149. Epub 2024 Nov 6.
5
Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis.羧基麦芽糖铁用于心力衰竭患者缺铁性贫血的系统评价与荟萃分析。
Future Sci OA. 2024 Dec 31;10(1):2367956. doi: 10.1080/20565623.2024.2367956. Epub 2024 Jul 9.
6
Intravenous Iron Technique Evaluation in Chronic Heart Failure With Iron Deficiency Anemia.缺铁性贫血慢性心力衰竭患者静脉补铁技术评估
Cureus. 2023 Oct 27;15(10):e47778. doi: 10.7759/cureus.47778. eCollection 2023 Oct.
7
Iron Deficiency in Heart Failure: A Korea-Oriented Review.心力衰竭中的缺铁:一项以韩国为导向的综述。
Int J Heart Fail. 2023 Oct 25;5(4):173-183. doi: 10.36628/ijhf.2023.0032. eCollection 2023 Oct.
8
Sex Differences in Heart Failure: What Do We Know?心力衰竭中的性别差异:我们了解什么?
J Cardiovasc Dev Dis. 2023 Jun 29;10(7):277. doi: 10.3390/jcdd10070277.
9
Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.血红蛋白水平与静脉注射羧甲麦芽糖铁治疗急性心力衰竭伴缺铁患者疗效的关系:AFFIRM-AHF 亚组分析。
Circulation. 2023 May 30;147(22):1640-1653. doi: 10.1161/CIRCULATIONAHA.122.060757. Epub 2023 Apr 13.
10
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.铁羧基麦芽糖静脉注射治疗缺铁性和急性心力衰竭患者的疗效与缺血病因的关系:来自 AFFIRM-AHF 试验的见解。
Eur J Heart Fail. 2022 Oct;24(10):1928-1939. doi: 10.1002/ejhf.2630. Epub 2022 Sep 23.